LIght Sedation Pressure Support (LIPS)
Primary Purpose
ARDS, Human
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
decrease of sedation doses and switch of ventilator settings
Sponsored by
About this trial
This is an interventional treatment trial for ARDS, Human
Eligibility Criteria
Inclusion Criteria:
- ARDS (Berlin definition)
- social insurance
Exclusion Criteria:
- neuromuscular disorders
- pregnancy
- need for muscular paralysis
- need for deep neurosedation
- more than 24hrs of artificial ventilation
- cystic fibrosis
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
light sedation pressure support ventilation
Arm Description
Outcomes
Primary Outcome Measures
transpulmonary pressure at early stabilization of patient
transpulmonary pressure (Paw - Peso < 24 cmH2O)
Secondary Outcome Measures
oxygenation modification
PaO2/FiO2
arterial pressure modification
Mean arterial pressure
Heart rate modification
heart rate
vasopressor dose modification
vasopressor dose in norepinephrine equivalent
acquired neuromyopathy
MRC <48/60
muscular volume decrease
quadriceps volume assessed by echography
ventilator free days
ventilator free days until day 28
delirium in ICU
CAM-ICU is a valid and reliable delirium assessment tool recommended by the Society of Critical Care Medicine (SCCM) in its 2013 Pain, Agitation and Delirium (PAD) guidelines. the presence of delirium is confirmed in the presence of criteria 1, 2 and 3 or 4.
change of the functional respiratory parameters from baseline at 6 months
vital capacity, total pulmonary capacity,
PTSD
post traumatic stress disorder impact of event scale > 33 tems are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") and the total score (ranging from 0 to 88)
number of auto extubation
Full Information
NCT ID
NCT03783468
First Posted
December 11, 2018
Last Updated
March 14, 2022
Sponsor
University Hospital, Lille
1. Study Identification
Unique Protocol Identification Number
NCT03783468
Brief Title
LIght Sedation Pressure Support
Acronym
LIPS
Official Title
Early LIght Sedation Pressure Support in ARDS Patients
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Withdrawn
Why Stopped
decision
Study Start Date
December 2021 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sedation may have many drawbacks in ICU patients: cardiovascular, neurologic, muscular.
Light sedation and Pressure Support ventilation is feasible in ARDS patients. However spontaneous breathing can lead to high transpulmonary pressure.
The goal of the study is to measure transpulmonary pressure before sedation decrease and after stabilization. The main endpoint is transpulmonary pressure less than 24 cmH2O.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ARDS, Human
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
light sedation pressure support ventilation
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
decrease of sedation doses and switch of ventilator settings
Intervention Description
tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
Primary Outcome Measure Information:
Title
transpulmonary pressure at early stabilization of patient
Description
transpulmonary pressure (Paw - Peso < 24 cmH2O)
Time Frame
when patient is conscious and stable (no modification of ventilator settings) generally within 2 hours
Secondary Outcome Measure Information:
Title
oxygenation modification
Description
PaO2/FiO2
Time Frame
stabilization of ventilator settings; 1hour after stabilization of ventilator settings
Title
arterial pressure modification
Description
Mean arterial pressure
Time Frame
stabilization of ventilator settings; 1hour after stabilization of ventilator settings
Title
Heart rate modification
Description
heart rate
Time Frame
stabilization of ventilator settings;1hour after stabilization of ventilator settings
Title
vasopressor dose modification
Description
vasopressor dose in norepinephrine equivalent
Time Frame
stabilization of ventilator settings ; 1hour after stabilization of ventilator settings
Title
acquired neuromyopathy
Description
MRC <48/60
Time Frame
ICU discharge, an average 16 days
Title
muscular volume decrease
Description
quadriceps volume assessed by echography
Time Frame
at 24 hours; at day of extubation; ICU discharge, an average 16 days
Title
ventilator free days
Description
ventilator free days until day 28
Time Frame
during the first 28 days
Title
delirium in ICU
Description
CAM-ICU is a valid and reliable delirium assessment tool recommended by the Society of Critical Care Medicine (SCCM) in its 2013 Pain, Agitation and Delirium (PAD) guidelines. the presence of delirium is confirmed in the presence of criteria 1, 2 and 3 or 4.
Time Frame
ICU discharge, an average 16 days
Title
change of the functional respiratory parameters from baseline at 6 months
Description
vital capacity, total pulmonary capacity,
Time Frame
at 6 months
Title
PTSD
Description
post traumatic stress disorder impact of event scale > 33 tems are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely") and the total score (ranging from 0 to 88)
Time Frame
at 6 months
Title
number of auto extubation
Time Frame
whatever until ICU discharge, an average 16 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ARDS (Berlin definition)
social insurance
Exclusion Criteria:
neuromuscular disorders
pregnancy
need for muscular paralysis
need for deep neurosedation
more than 24hrs of artificial ventilation
cystic fibrosis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Geoffrey Ledoux, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
LIght Sedation Pressure Support
We'll reach out to this number within 24 hrs